EVER Neuro Pharma GmbH
About EVER Neuro Pharma GmbH
Certifications
Categories
-
Country/Region:Austria
-
On CPHI since:2015
-
Certificates:2
-
Employees:1000 - 4999
Company types
Primary activities
Meet us at
CPHI Milan 2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
Products from EVER Neuro Pharma GmbH (7)
-
Product Cabazitaxel EVER Pharma: 45mg/4.5ml + 50mg/5ml + 60mg/60ml - Single liquid vial
Cabazitaxel EVER Pharma is provided as a single vial, ready to dilute formulation and is available in vial sizes covering the common range of patient specifi c doses for economy and convenience Cabazitaxel is a third-generation antineoplastic taxane and was the fi rst therapy to show a survival benefi t fo... -
Product EVER Pharma Product List
Our products include: Atosiban Cabazitaxel Cebrium(R) Cerebrolysin(R) Dacepton(R) Dexmedetomidine Docetaxel Fulvestrant MemoProve(R) Oxytocin Paclitaxel Pemetrexed Tachyben(R) Terlipressin -
Product CDMO: Contract Development
EVER is a leader in pharmaceutical development
Our end-to-end service covers every aspect of pharmaceutical development, from API selection to final process validation and quality assurance, with the highest level of expertise.
With ‘state of the art’ labs in Unterach ... -
Product CDMO: Contract Manufacturing
EVER Pharma is a specialist in the manufacture of complex injectable products such as low oxygen formulations, crystal suspensions and oily solutions. This includes many highly active substances such as narcotics, hormones and cytotoxics.
Our state-of-the-art facility utilizes the latest innovatio... -
Product EVER Pharma: Product Portfolio - 2025
Our products include: • Atosiban • Bortezomib • Cabazitaxel • Cerebrolysin • Dacepton (Apomorphine) • Dexemedetomidine • Docetaxel • Eribulin • Fulvestrant • MemoProve • Oxytocin • Paclitaxel • Pemetrexed • Testosterone Enantate • Testosterone Undecanoate • Tachyben (Ur... -
Product Azacitidine EVER Pharma
Azacitidine is a cytotoxic hypomethylating chemical analogue of cytidine used in the treatment of myelodysplastic syndromes.
Azacitidine EVER Pharma is available in both the standard 100 mg vial size and a new 150 mg vial size aligned to the most common patient doses to minimize waste... -
Product Fulvestrant EVER Pharma
The first Fulvestrant in Europe approved for storageat room temperature.
EVER Neuro Pharma GmbH Resources (17)
-
News EVER Pharma gains EU Marketing Authorization for Trabectedin
EVER Pharma announces the EU-wide marketing authorization of Trabectedin (in 0.25MG and 1MG vial sizes) for the treatment of advanced soft tissue sarcoma and ovarian cancer -
Datasheet 2025 Product List (PDF)
Our products include:
AtosibanCabazitaxelCerebrolysinDacepton (Apomorphine)DexemedetomidineDocetaxelEribulinFulvestrantMemoProveOxytocinPaclitaxelPemetrexedTestosterone EnantateTestosterone UndecanoateTachyben (Urapidil)TerlipressinTrabectedin -
News EVER Pharma Expands Operations with Opening of New Manufacturing Facility in Jena, Germany
EVER Pharma Expands Operations with Opening of New Manufacturing Facility in Jena, Germany -
Brochure EVER CDMO: Contract Manufacturing
Contract Manufacturing Overview -
News EVER Pharma Announces Approval of Testosterone Undecanoate in the EU
EVER Pharma has announced the approval of Testosterone Undecanoate in the European Union for the treatment of male hypogonadism. -
Brochure EVER CDMO: Contract Development
Overview on EVER's contract development services -
News EVER Pharma Gained EU-Approval of Testosterone Enantate
EVER Pharma, a fully integrated specialty pharmaceuticals company, is pleased toannounce the approval of Testosterone Enantate in the European Union for thetreatment of male hypogonadism. This condition, characterized by insufficienttestosterone production, affecting up to 10% of men globally and 40% of men aged 45. -
Brochure Trabectedin EVER Pharma
0.25mg + 1mg -
News EVER Pharma gained EU-Approval for Advanced Cancer Treatment
EVER Pharma, a fully integrated specialty pharmaceuticals company, announced the approval of Eribulin in the European Union. Eribulin is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.
-
Brochure Fulvestrant EVER Pharma
PFS - 250mg/5ml -
News EVER Pharma receives EU approval for a liquid ready to use Bortezomib formulation
EVER Pharma is pleased to announce EU-wide approval of Bortezomib for the treatment of patients with multiple myeloma and mantle cell lymphoma -
Brochure Terlipressin EVER Pharma
1mg/5ml + 2mg/10ml -
Brochure Atosiban EVER Pharma
6.75mg/0.9ml + 37.5/5ml + 75mg/10ml -
Brochure Bortezomib EVER Pharma
2.5mg/1ml + 3.5mg/1.4ml






